This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Dronabinol for muscle spasticity caused by multiple sclerosis

< Back

Dronabinol for muscle spasticity caused by multiple sclerosis


Musculoskeletal, Neurology and Neurosurgery

July 2021

Dronabinol is in clinical development for the treatment of spasticity caused by multiple sclerosis (MS). MS is a long-term condition that affects the brain and spinal cord, causing a range of symptoms including spasticity. Spasticity is when the muscles become stiff and resistant to movement, which can be extremely painful. There are currently limited treatment options for patients with spasticity caused by MS.
Dronabinol, administered orally, is a synthetic (artificial) form of the psychoactive component of cannabis, which means it can cause changes to cognitive/emotional processes and reduces pain. Dronabinol may reduce spasticity although the precise mechanism for this effect has not been elucidated. If licensed, dronbionol will offer an additional treatment option for adults with spasticity caused by MS.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts